Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription

MLA

T B, McNeely, et al. “Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by Secretory Leukocyte Protease Inhibitor Occurs Prior to Viral Reverse Transcription.” Blood, vol. 90, no. 3, Aug. 1997. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........ca22de370f77fcc8524090446174d004&authtype=sso&custid=ns315887.

APA

T B, M., D C, S., M, R., C, T., S P, E., & S M, W. (1997). Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood, 90(3).

Chicago

T B, McNeely, Shugars D C, Rosendahl M, Tucker C, Eisenberg S P, and Wahl S M. 1997. “Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by Secretory Leukocyte Protease Inhibitor Occurs Prior to Viral Reverse Transcription.” Blood 90 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........ca22de370f77fcc8524090446174d004&authtype=sso&custid=ns315887.